Bextra class action Philadelphia

Bextra

Bextra® class action in Philadelphia are being filed due to the FDA announcing that it has asked Pfizer, Inc. to withdraw Bextra from the market "because the overall risk versus benefit profile for the drug is unfavorable."

To report any unexpected adverse or serious events associated with the use of Bextra® contact the FDA MedWatch program at 1-800-FDA-1088 or on the above link.

Bextra® is a COX-2 selective agent. It is prescribed for inflammation and pain from arthritis or menstrual cramping. Other drugs in this class include Celebrex® and Vioxx®. Many doctors switched patients from Vioxx® to Bextra® when Merck voluntarily removed it from the market due studies showing an increased risk for heart attack and stroke.

bextra site map

For additional information, try these sites:

For a free case evaluation from a Philadelphia attorney, click here: http://www.lawforum.net/areas/bextra/pennsylvania/philadelphia/
Munley, Munley & Cartwright, P.C. is a Pennsylvania law office which has breaking news and information about this lawsuit http://www.munley.com/drugs/bextra.html
Click here to read the FDA questions and answers about strengthened warnings on Bextra® boxes http://www.fda.gov/cder/drug/infopage/bextra/bextraQA.htm

Autism Education Materials!